Pharsight

Drugs that contain Ribavirin

1. Rebetol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6524570 SCHERING Polyethylene glycol modified interferon therapy
Nov, 2016

(7 years ago)

US6461605 SCHERING Continuous low-dose cytokine infusion therapy
Nov, 2016

(7 years ago)

US6177074 SCHERING Polyethylene glycol modified interferon therapy
Nov, 2016

(7 years ago)

US6524570

(Pediatric)

SCHERING Polyethylene glycol modified interferon therapy
May, 2017

(7 years ago)

US6461605

(Pediatric)

SCHERING Continuous low-dose cytokine infusion therapy
May, 2017

(7 years ago)

US6177074

(Pediatric)

SCHERING Polyethylene glycol modified interferon therapy
May, 2017

(7 years ago)

US6472373 SCHERING Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Sep, 2017

(6 years ago)

US6172046 SCHERING Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Sep, 2017

(6 years ago)

US6472373

(Pediatric)

SCHERING Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Mar, 2018

(6 years ago)

US6172046

(Pediatric)

SCHERING Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Mar, 2018

(6 years ago)

US6790837 SCHERING Ribavirin syrup formulations
Apr, 2023

(1 year, 2 months ago)

US6790837

(Pediatric)

SCHERING Ribavirin syrup formulations
Oct, 2023

(8 months ago)

Market Authorisation Date: 29 July, 2003

Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...

Dosage: SOLUTION;ORAL

How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage

REBETOL family patents

Family Patents

2. Rebetol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6461605 MERCK SHARP DOHME Continuous low-dose cytokine infusion therapy
Nov, 2016

(7 years ago)

US6177074 MERCK SHARP DOHME Polyethylene glycol modified interferon therapy
Nov, 2016

(7 years ago)

US6524570 MERCK SHARP DOHME Polyethylene glycol modified interferon therapy
Nov, 2016

(7 years ago)

US6524570

(Pediatric)

MERCK SHARP DOHME Polyethylene glycol modified interferon therapy
May, 2017

(7 years ago)

US6461605

(Pediatric)

MERCK SHARP DOHME Continuous low-dose cytokine infusion therapy
May, 2017

(7 years ago)

US6177074

(Pediatric)

MERCK SHARP DOHME Polyethylene glycol modified interferon therapy
May, 2017

(7 years ago)

US6472373 MERCK SHARP DOHME Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Sep, 2017

(6 years ago)

US6172046 MERCK SHARP DOHME Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Sep, 2017

(6 years ago)

US6472373

(Pediatric)

MERCK SHARP DOHME Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Mar, 2018

(6 years ago)

US6172046

(Pediatric)

MERCK SHARP DOHME Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Mar, 2018

(6 years ago)

Market Authorisation Date: 03 June, 1998

Treatment: Method of treating hepatitis c viral infection by continuous parenteral admin interferon alpha 2-10 million iu weekly, subcutaneously, injection of polymer-interferon alpha conjugate-polymer is peg-in...

Dosage: CAPSULE;ORAL

How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage

REBETOL family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Virazole patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6150337 BAUSCH Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
Nov, 2017

(6 years ago)

Market Authorisation Date: 31 December, 1985

Treatment: Use of ribavirin to increase type 1 cytokine response and suppress type 2 cytokine resp0nse to lymphocytes, including methods that take advantage of such modulation to treat infections and infestation...

Dosage: FOR SOLUTION;INHALATION

How can I launch a generic of VIRAZOLE before it's drug patent expiration?
More Information on Dosage

VIRAZOLE family patents

Family Patents